Outpatient antibiotic use in Dutch infants after 10-valent pneumococcal vaccine introduction: a time-series analysis

被引:7
|
作者
Fortanier, Alexandre C. [1 ]
Venekamp, Roderick P. [1 ]
Stellato, Rebecca K. [1 ]
Sanders, Elisabeth A. M. [2 ,3 ]
Damoiseaux, Roger A. M. J. [1 ]
Hoes, Arno W. [1 ]
Schilder, Anne M. [1 ,4 ]
机构
[1] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[2] Univ Utrecht, Univ Med Ctr, Dept Paediat Immunol & Infect Dis, Utrecht, Netherlands
[3] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[4] UCL, Ear Inst, evidENT, London, England
来源
BMJ OPEN | 2018年 / 8卷 / 06期
关键词
CONJUGATE VACCINE; OTITIS-MEDIA; IMPACT; CHILDREN; HOSPITALIZATION; PROGRAMS; TRENDS;
D O I
10.1136/bmjopen-2017-020619
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective This population-based cohort study assesses the impact of switching from a 7-valent pneumococcal conjugate vaccine (PCV) to a 10-valent PCV on outpatient antibiotic use in Dutch infants, and whether geographical vaccination coverage modifies this association. Setting and participants We extracted 2006-2013 anonymised antibiotic purchase data of 255 154 Dutch infants aged below 2 years from Achmea Health, a health insurance fund covering 28% of the national population. Design and main outcome measure Changes in monthly antibiotic use from 2006-2011 (PCV7) to 2011-2013 (PCV10) were estimated using time-series analysis accounting for seasonality and autocorrelation. Interaction terms for vaccination coverage (categorised into seven groups) and period were added to the model to test whether this association was vaccination coverage dependent. Results 275337 antibiotic courses were used by 119 078 infants (461 352 person-years). PCV10 introduction was associated with a modest 1.6% overall reduction in antibiotic use (purchase rate ratio: 0.98, 95% CI: 0.98 to 0.99). Our model showed a significant difference in time trend in antibiotic use after PCV10 introduction (p=0.0084) with an increase in prescriptions in the PCV7 period (slope: 0.0023/month, 95% CI: -0.0001 to 0.0047) versus a decline in the PCV10 period (slope: -0.0089/month, 95% CI: -0.0150 to -0.0029). There was no evidence that PCV vaccination coverage affected this association, but since the largest rate ratios were observed in municipalities with the lowest vaccine coverage and had very wide accompanying Cls, our study might have insufficient power to detect such an association. Conclusions Switching from PCV7 to PCV10 was associated with a modest decline in outpatient antibiotic use in Dutch infants.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
    Shrestha, Shrijana
    Gurung, Meeru
    Amatya, Puja
    Bijukchhe, Sanjeev
    Bose, Anindya Sekhar
    Carter, Michael J.
    Gautam, Madhav C.
    Gurung, Sunaina
    Hinds, Jason
    Kandasamy, Rama
    Kelly, Sarah
    Khadka, Bibek
    Maskey, Pratistha
    Mujadidi, Yama F.
    O'Reilly, Peter J.
    Pokhrel, Bhishma
    Pradhan, Rahul
    Shah, Ganesh P.
    Shrestha, Sonu
    Wahl, Brian
    O'Brien, Katherine L.
    Knoll, Maria Deloria
    Murdoch, David R.
    Kelly, Dominic F.
    Thorson, Stephen
    Voysey, Merryn
    Pollard, Andrew J.
    LANCET GLOBAL HEALTH, 2022, 10 (10): : E1494 - E1504
  • [12] Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
    Wasserman, Matthew
    Gabriela Palacios, Maria
    Gabriela Grajales, Ana
    Baez Revueltas, F. Berenice
    Wilson, Michele
    McDade, Cheryl
    Farkouh, Raymond
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 560 - 569
  • [13] Pneumococcal meningitis before the introduction of 10-valent pneumococcal conjugate vaccine into the National Childhood Immunization Program in Poland
    Polkowska, Aleksandra
    Skoczynska, Anna
    Paradowska-Stankiewicz, Iwona
    Stefanoff, Pawel
    Hryniewicz, Waleria
    Kuch, Alicja
    Lyytikainen, Outi
    Nuorti, J. Pekka
    VACCINE, 2019, 37 (10) : 1365 - 1373
  • [14] Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
    Hirose, Tatiane E.
    Maluf, Eliane M. C. P.
    Rodrigues, Cristina O.
    JORNAL DE PEDIATRIA, 2015, 91 (02) : 130 - 135
  • [15] Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
    Richter, Lukas
    Schmid, Daniela
    Kanitz, Elisabeth Eva
    Zwazl, Ines
    Poellabauer, Eva
    Jasinska, Joanna
    Burgmann, Heinz
    Kundi, Michael
    Wiedermann, Ursula
    PLOS ONE, 2019, 14 (01):
  • [16] Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
    Perdrizet, Johnna
    Santana, Carlos Felipe S.
    Senna, Thais
    Alexandre, Rodrigo Fernandes
    de Almeida, Rodrigo Sini
    Spinardi, Julia
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 1162 - 1172
  • [17] Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis
    Reyburn, Rita
    Tuivaga, Evelyn
    Nguyen, Cattram D.
    Ratu, Felisita T.
    Nand, Devina
    Kado, Joe
    Tikoduadua, Lisi
    Jenkins, Kylie
    de Campo, Margaret
    Kama, Mike
    Devi, Rachel
    Rafai, Eric
    Weinberger, Daniel M.
    Mulholland, E. Kim
    Russell, Fiona M.
    LANCET GLOBAL HEALTH, 2021, 9 (01): : E91 - E98
  • [18] Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis
    Silaba, Micah
    Ooko, Michael
    Bottomley, Christian
    Sande, Joyce
    Benamore, Rachel
    Park, Kate
    Ignas, James
    Maitland, Kathryn
    Mturi, Neema
    Makumi, Anne
    Otiende, Mark
    Kagwanja, Stanley
    Safari, Sylvester
    Ochola, Victor
    Bwanaali, Tahreni
    Bauni, Evasius
    Gleeson, Fergus
    Knoll, Maria Deloria
    Adetifa, Ifedayo
    Marsh, Kevin
    Williams, Thomas N.
    Kamau, Tatu
    Sharif, Shahnaaz
    Levine, Orin S.
    Hammitt, Laura L.
    Scott, J. Anthony G.
    LANCET GLOBAL HEALTH, 2019, 7 (03): : E337 - E346
  • [19] Clinical and epidemiological characteristics of severe community-acquired pneumonia in children after introduction of the 10-valent pneumococcal vaccine
    Lima, Eduardo J. F.
    Mello, Maria J. G.
    Albuquerque, Maria F. P. M.
    Lopes, Maria I. L.
    Serra, George H. C.
    Abreu-Lima, Maria A. Z.
    Correia, Jailson B.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2015, 6 : 131 - 138
  • [20] Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil
    Christovam Sartori, Ana Marli
    de Soarez, Patricia Coelho
    Dutilh Novaes, Hillegonda Maria
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2012, 66 (03) : 210 - 217